Randomized Clinical Study of Maintenance Therapy with immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Trial Profile

Randomized Clinical Study of Maintenance Therapy with immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms IMPULSE
  • Sponsors Mologen
  • Most Recent Events

    • 20 Oct 2017 This trial has been completed in spain.
    • 13 Sep 2017 According to a Mologen AG media release, the company expects a final read-out probably in the first quarter of 2018, approximately 24 months following the recruitment of the last patient.
    • 13 Sep 2017 Results published in an Mologen AG media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top